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A 28-year-old black male was referred to the Hypertension Clinic at
New England Medical Center for evaluation of high blood pressure.
Two days earlier, when he was seen in the Emergency Room with an
upper respiratory tract infection, his blood pressure was 140/116 mm
Hg. Treatment was prescribed for the respiratory symptoms. No
laboratory studies other than a throat culture were performed. When he
was seen 2 days later in the Hypertension Clinic, he was feeling well.
Three years earlier the patient had been told he had elevated blood
pressure during an insurance physical examination. He could not recall
the level of his blood pressure; the insurance was approved, however.
No antihypertensive therapy was prescribed during the intervening
period. The only other significant medical history was related to
proteinuria, which had been detected during a military induction
physical 10 years earlier. No protein was found in the urine at the time
of the insurance examination. The patient described himself as a
healthy, active individual without medical complaints. He had no
weight loss, anxiety episodes, depression, night sweats, easy fatigabil-
ity, or persistent respiratory complaints. He had never had an abnormal
chest x-ray, and he had never used vitamin D preparations or thiazide
diuretics. He was employed full time as a shipping clerk; he did not
smoke, but he consumed large amounts of alcohol intermittently.
Physical examination revealed a thin, well-developed, well-nour-
ished, young black male in no acute distress. The blood pressure was
148/100 mm Hg in the right arm when he was recumbent and 150/105
mm Hg in the right arm when he stood. Blood pressures in the left arm
were similar. His pulse was 100 beats/mm and regular. Pertinent
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physical findings included normal eye grounds, except for some early
arteriolar narrowing. The thyroid was barely palpable, and no other
masses or nodes were detected. The chest was clear to auscultation and
percussion. Cardiac examination disclosed a normal PMI, and normal
sounds were noted except for a grade l/Vl systolic ejection murmur at
the left sternal border radiating to the apex. The abdomen was flat and
nontender with no organomegaly; normal bowel sounds were present.
No bruits were noted. The genitourinary examination revealed a
normally developed male. Musculoskeletal and neurologic examina-
tions were within normal limits. No clubbing, edema, or cyanosis was
evident in the extremities. His skin was warm, dry, and without any
lesions. No lymphadenopathy was detected.
Urinalysis showed a pH of 6, trace protein, negative glucose,
negative blood, and a benign sediment. Serum creatinine was 1.1 mg/dl;
BUN, 22 mg/dl; sodium, 136 mEq/liter; potassium, 4.4 mEq/liter;
chloride, 95 mEq/liter; and carbon dioxide, 24 mEq/liter. Serum total
calcium was 11.6 mg/dl; phosphorus. 3.3 mg/dl; fasting glucose, 80
mg/dl; uric acid, 9.6 g/dl; albumin, 4.2 g/dl; cholesterol. 240 mgldl; and
triglycerides. 75 mg/dl. The T3 was 165 ngldl (normal, 70—170 ngldl); T4,
3.8 ng/dl; alkaline phosphatase, 2.2 (Bodansky units); hematocrit,
48.2%; hemoglobin, 16.8; and white blood cell count, 10,700 mm3 with
a normal differential. The 24-hour urine protein excretion was 17—26
mg. A 24-hour urine collection contained 117 mEq of sodium and 14
mEq of calcium. The PTH level was 94 pg/mI (normal 15—30, N-
terminal). Serum protein electrophoresis was normal. The PPD was
negative. Two plain chest films were negative. An intravenous pyelo-
gram was normal. Electrocardiogram was unrevealing. Plain films of the
hands revealed no evidence of subperiosteal resorption.
Over the next 5 months, the blood pressure ranged between
125—145/85—95 mm Hg. No other medical problems were identified,
except for persistent elevation of the serum total calcium. The repeat
values for the serum calcium and phosphorus concentrations, respec-
tively, were: 10.8 mg/dI and 2.6 mg/dl; 11.3 and 3.1 mgldl; 11.8 and 2.6
mg/dl; 10.9 and 2.1 mg/dl.
Because of persistent hypercalcemia, elevated P'I'H levels, and a
failure to identify an alternative basis for his hypercalcemia, the patient
was admitted to the Surgical Service for surgery. At the time of
admission, laboratory studies revealed: sodium, 138 mEq/liter; potas-
sium, 4.2 mEq/liter; chloride, 97 mEq/liter; bicarbonate, 27 mEq/liter;
serum total calcium, 11.1 mg/dl; phosphorus, 3.6 mgldl; albumin, 4.3
gldl; and a normal complete blood count. The left superior and inferior
parathyroid glands were identified and biopsied. The right inferior
parathyroid gland also was identified, and was excised along with the
right lobe of the thyroid. The latter was removed in an attempt to locate
the right superior parathyroid gland. Examination of the pathologic
specimens revealed tissue from four parathyroid glands. Adenomatous
changes were not noted in any of the specimens. The presence of
hyperplasia was not mentioned, and the total volume of the excised
gland mass was not recorded.
During the first 6 postoperative months, serum calcium concentra-
tions ranged between 9.0 mg/dl and 10.2 mg/dl. Serum phosphorus
values were between 3.2 mg/dl and 4.1 mg/dl. Six months following the
neck exploration, the PTH again was measured. The reported value was
188 slEq/ml (normal, up to 85 dEq/ml; mixed N- and C-terminal
assay), with a simultaneous serum total calcium of 9.9 mg/dl. Repeated
PTH determinations 6 and 12 months later were 138 dEq/ml and 87
ilEq/ml respectively; concurrent serum total calcium levels were 10.0
mg/dl and 10.2 mg/dl.
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During the first 4 years after subtotal parathyroidectomy. the pa-
tient's blood pressure was recorded in the 130—I 50/90—l00 mm Hg
range. He was treated with hydrochlorothiazide, 50 mg/day, for a short
period during his second postoperative year, but on that regimen he
developed acute gout and the hydrochlorothiazide was discontinued.
Propranolol, 40 mg twice daily, was started, and the blood pressure fell
to 110—130/82—90 mm Hg.
Discussion
DR. DAVID A. MCCARRON (Professor of Medicine and Co-
head of the Division of Nephrology and Hypertension, and
Director ofthe National Dai,y Board Instil ute for Nutrition and
Cardiovascular Research, Department of Medicine, Oregon
Health Sciences University, Portland, Oregon): This patient's
presentation and clinical course provided both a historic and
pathophysiologic perspective on what has emerged as one of
the most active [1] yet controversial areas of cardiovascular
research [2, 31: the relationship of calcium metabolism to the
regulation of arterial pressure [41. This young black male, who
was referred to the Hypertension Clinic at New England
Medical Center over 10 years ago with chronic hypercalcemia
and hypertension, was responsible for initiating my interest in
the possibility that disregulation of the P1'H-Ca24 -vitamin D
axis was a factor in the development of hypertension in hu-
mans. At the time of his presentation, a search of the medical
literature for information on this topic failed to identify a critical
body of data and prompted the design of what I believe was the
first controlled clinical study of the association between blood
pressure status and parameters of calcium metabolism [5]. The
findings of that investigation and the subsequent research by
our laboratory at Oregon, as well as from many others over the
past decade, form the basis for considering the following
question: do dietary and physiologic factors that influence
calcium homeostasis contribute to the modulation of arterial
pressure in humans?
In attempting to answer that question, I will review a variety
of observations relevant to this patient's medical disorders. I
will return to this case after summarizing the current status of
research in this field. I will begin with observations derived
from epidemiologic studies of the interrelationships among
arterial pressure, dietary calcium intake, and calcium metabo-
lism in humans. I then will turn to laboratory investigations that
addressed many of the same issues in experimental models. I
will examine the clinical data and discuss the arterial pressure
effects of increasing calcium intake in humans, as well as
whether there are predictors of antihypertensive response to
this intervention. Finally, I will summarize our current under-
standing of the mechanisms that have been invoked to explain
how modifying calcium metabolism changes blood pressure in
humans and in the experimental animal.
Historic perspective
Unlike some areas of new investigation, the concepts relating
calcium to high blood pressure were introduced against a
background of historic facts and beliefs that would, at least
superficially, argue strongly against the possibility that chronic
depletion of calcium, and/or altered cell regulation of calcium
resulting in a functional depletion of the cation, raise arterial
pressure. These observations include the following seven
points. (1) Acute hypercalcemia was known to produce a rise in
arterial pressure in normal subjects and in individuals with renal
disease 161. (2) An association between high blood pressure and
primary hyperparathyroidism was well established [7]. (3) By
the 1970s vascular smooth muscle contraction was known to be
critically dependent on the release of intracellular calcium
stores [8]. (4) A circulating inhibitor of sodium transport was
thought to exist in at least a subset of hypertensive humans and
in some animal models of high blood pressure, and this notion
had come to dominate efforts to explain how intracellular free
calcium might be elevated [9]. (5) In large part because of the
sodium inhibitor hypothesis, some workers theorized that in-
tracellular free calcium was elevated in the vascular tissue of
experimental models and in humans with high blood pressure
[10]. (6) Agents called "calcium antagonists" or "calcium
channel blockers" had been identified as potentially effective
antihypertensive agents. For obvious semantic reasons, if a
calcium antagonist lowered blood pressure, it was difficult to
reconcile how a calcium-deficient state, particularly at a cellular
level, could contribute to the rise in arterial pressure. (7) From
a nutritional standpoint, interest in diet and heart disease was
principally focused on dietary excesses rather than on dietary
deficiencies. In the domain of hypertension, no concept was
more tightly embraced than that of excessive dietary sodium
intake being a primary factor in the development of high blood
pressure in humans [11].
Thus, in 1976, from virtually every vantage point (epidemi-
ology, physiology, cell biology, pharmacology, and nutrition),
data emerged that led to the hypothesis that calcium metabo-
lism was linked to the development of high blood pressure. The
corollary followed that exposing vascular tissue to excessive
amounts of calcium was responsible for hypertension. In fact,
when the initial clinical study was undertaken at New England
Medical Center that year, our working hypothesis was precisely
that. As the data from clinical and laboratory investigations
have accumulated over the past 13 years, that original hypoth-
esis became no longer tenable. In fact, the findings demanded
that new hypotheses relating calcium and blood pressure be
formulated.
Epidemiology
Biochemical parameters. In our initial clinical studies, we
found an 18% higher level of circulating parathyroid hormone
levels in patients with untreated essential hypertension than in
normotensive subjects with similar levels of serum total calcium
[5]. The higher parathyroid hormone levels could not be attrib-
uted to renal dysfunction, hut were associated with an increase
in urinary calcium excretion (when indexed against simulta-
neous urinary sodium excretion). This latter finding was inter-
preted as representing a renal "calcium leak" in hypertension.
In a subsequent metabolic balance study of the renal handling of
calcium in hypertension, we confirmed that urinary cAMP
excretion was elevated in hypertensive patients [12]. In a study
of young males, Grobbee and colleagues later documented that
parathyroid hormone values directly correlated with blood
pressure, after adjustment for body weight 1131. Strazzullo and
coworkers also reported higher levels of parathyroid hormone,
as well as higher levels of urinary cAMP excretion, in patients
with high blood pressure compared with normals [14]. Using
metabolic clearance studies, Strazzullo also documented higher
values for renal calcium clearance in patients with mild essen-
tial hypertension when compared with appropriate control
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subjects. An association between increased urinary calcium
excretion and high blood pressure also was reported in a large
population survey [15]. This relationship was interpreted as
reflecting an increase in dietary calcium intake in hypertensive
patients, although calcium intake was not directly assessed in
this study. In our first intervention trial at Oregon, we found
that the urinary calcium excretion rate was somewhat higher,
even though dietary calcium intake was somewhat lower, in
hypertensive subjects compared with normotensive individuals;
however, these differences were not statistically significant
[16]. We interpreted these observations as being more in
keeping with a "renal calcium leak" than with an excessive
intake of calcium as an explanation for the high urinary calcium
excretion previously noted in hypertensive humans.
In several epidemiologic surveys, serum total calcium con-
centration has been directly associated with blood pressure,
although in some studies this relationship might reflect differ-
ences in serum albumin concentration [15, 17]. In our index
report of the relationship of serum ionized calcium to blood
pressure, hypertensive patients had lower serum ionized cal-
cium values than did the control group [18]. In subsequent
reports, serum ionized calcium values have been either identi-
cal or modestly reduced in subjects with high blood pressure
compared with those with normal blood pressure [19, 201. In a
carefully investigated population in Minnesota, ultrafilterable
calcium (P =
.01) and serum ionized calcium (P = .07) were
lower in individuals with increased arterial pressure [21]. Res-
nick et al have reported that this relationship depends on renin
status: patients with low renin activity have lower ionized
calcium, whereas patients with high renin activity have higher
ionized calcium values [20]. In collaboration with the Cornell
group, we recently confirmed the stratification of serum ionized
calcium by renin status [22]. Strazzullo and coworkers noted
that serum ionized calcium at baseline was nearly identical in
normotensive and hypertensive subjects but that, following an
acute calcium infusion, serum ionized calcium increased to a
significantly lesser degree in the hypertensives [141. Two stud-
ies have reported higher levels of serum ionized calcium con-
centration in hypertensive subjects, but in both, thiazide diuret-
ics (which increase serum ionized calcium values when used
chronically) had been administered to many of the subjects [23,
24].
The relationship of serum phosphorus to high blood pressure
has been much more consistent than has that of serum calcium
to high blood pressure. Virtually all reports in the medical
literature have identified either lower serum phosphorus values
in hypertensive patients or an inverse correlation between
serum phosphorus and arterial pressure in the population stud-
ied [5, 25].
In our recent study of serum 1,25 dihydroxyvitamin D3 levels
in normotensive individuals and in those with untreated hyper-
tension, we found lower levels of 1,25(OH)D3 in the hyperten-
sive subjects [26]. We simultaneously measured serum phos-
phorus, serum ionized calcium, and serum parathyroid
hormone levels using a two-site, intact-molecule chemilumino-
metric assay [27]. Among males, parathyroid hormone levels
correlated significantly and directly with both supine and stand-
ing systolic, diastolic, and mean arterial pressure. Among
females, no such correlation was detected. Likewise, serum
phosphorus values significantly and inversely correlated with
arterial pressure in males but not in females. Serum ionized and
total calcium values did not, however, correlate with blood
pressure in the male subjects. Somewhat confusingly, serum
total calcium correlated significantly and directly with blood
pressure in females. What has emerged from this study is a
picture of increased parathyroid hormone function in male
hypertensives (with concurrent reductions in serum phosphorus
values) and minimal, if any, reductions in serum ionized cal-
cium values. Although this constellation of biochemical findings
in male subjects normally would evoke an increase in circulat-
ing l,25(OH)D3 levels, precisely the opposite was observed
[261.
I speculate that the pattern of biochemical parameters of
calcium metabolism associated with hypertension is most con-
sistent with a subtle degree of whole-organism calcium deple-
tion with a secondary increase in parathyroid gland function.
However, these defects in calcium homeostasis relate to blood
pressure primarily in male subjects. This most recent observa-
tion may account for the inconsistencies in measured markers
of calcium metabolism in hypertensive individuals in epidemi-
ologic reports.
Dietary calcium. One of the questions prompted by our initial
studies was whether dietary calcium intake was different in
patients with hypertension than in normotensive individuals.
The results from a pilot study in 1982 provided the first evidence
that reduced dietary calcium intake was associated with hyper-
tension [28], Of 19 nutrients measured, only a 22% reduction in
calcium intake distinguished the hypertensive from the normo-
tensive subjects. We then turned to the National Health and
Nutrition Examination Survey I (NHANES I) data base to
determine whether such a relationship was evident in a repre-
sentative population of adult Americans [291. Figure 1 derives
from our analysis of those data from the National Center for
Health Statistics. As we reported in 1984, of the nutritional
factors assessed in that survey, dietary calcium was the best
single predictor of an individual's blood pressure. The more
dietary calcium consumed, the lower an individual's blood
pressure and the lower the probability of having blood pressure
in the hypertensive range.
At least 23 subsequent publications in the medical literature
have verified the finding of an inverse relationship between
dietary calcium intake and blood pressure. Those studies are
summarized in Table 1 [16, 21, 28—50]. In addition to our
assessment of NHANES I, six other groups have utilized the
same data base; five of these groups have reported similar
findings even though sample sizes, definition of blood pressure
status, and statistical techniques varied greatly [51]. The au-
thors of the one discrepant report recently acknowledged that
an alternative analysis did reveal a relationship between lower
dietary calcium intake and higher blood pressure dependent on
consumption of a high-sodium diet [35].
Whereas all other reports are based on cross-sectional pop-
ulation studies, Witteman et al utilized a survey of 58,218
females in the United States to determine prospectively the
frequency with which hypertension was diagnosed over a
4-year period [49]. After adjustment for age, body weight, and
alcohol consumption, a logistic regression model showed di-
etary calcium and dietary magnesium to have independent,
inverse associations with hypertension. The relative risk for the
development of hypertension was 0.78 at a dietary calcium
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Fig. 1. Percentage of individuals in upper
10% of systolic blood pressure distribution
(adjusted for decade of life, gender, and race)
based on level of dietary calcium intake. Data
derived from NHANES 1 survey [29].
Table I. Epidemiologic studies of calcium and hypertension
Author Population
Dietary
dataa Calcium source
Subjects
Age Sex Other dietary componentsNo.
McCarron, 1982 [28] Portland, OR 24-hr Diet 96 25—65 MF Magnesium
McCarron, 1984 [29] NHANES 1 24-hr Diet 10,419 18—74 MF Potassium, vitamins C, A
Ackley, 1983 [30] San Diego, CA Quest Dairy products 5,050 30—79 MF —
Garcia-Palmieri, 1984 [31]
Harlan, 1984 [32]
Puerto Rico
NHANES 1
24-hr
24-hr
Diet/milk
Diet
7,932
2,055
45—64
25—74
M
MF
Alcohol, coffee
Alcohol, phosphorus
Nichaman, 1984 [33] Chicago, IL History Diet 1,652 40—56 M Polyunsat. fatty acid,
alcohol
Gruchow, 1985 (34], NHANES I 24-hr Diet — 18—74 MF Alcohol, sodium,
1986 [35] potassium
Harlan, l985 [36] NHANES 1 24-hr Diet Alcohol, phosphorus
Harlan, 1985 (37] NHANES I 24-hi, freq Diet —
Johnson, 1985 1381 Wisconsin Record Diet —
Kromhout, l985 [39] Netherlands History Diet Phosphorus, alcohol
McCarron, 1985 [16] Portland, OR 24-hr Diet —
Reed, 1984 (40] Honolulu, HI 24-hr Diet/milk Phosphorus, protein
Sempos, 1985 [4l] NHANES I 24-hr Diet —
Yamamoto, 1985 [42) Pittsburgh, PA Freq Diet —
Caggiula, 1986 [431 MRFIT 24-hr Diet Potassium, alcohol,
polyunsaturated fatty
acid
Folsom, 1986 [21] Minnesota Freq Dairy products
Kok, 1986 [44] Netherlands History Diet
Trevisan, 1986 [45] Italy Freq Milk —
Liebman, 1986 [46] SE USA 24-hr Dairy products, diet Sodium, potassium
Sempos, 1986 (47] NHANES I, 11 24-hr Diet —
Joifres, 1987 [48] Honolulu, HI 24-hr Diet Magnesium, fiber,
potassium
Witteman, 1987 [491 US nurses study 24-hr Diet 58,218 34—59 F Magnesium, alcohol
McGarvey, 1988 [50] Providence, RI Quest Maternal diet 212 0—Ol MF Magnesium, potassium
3,854
5,305
113
605
80
6,496
5,858
1,937
25—74
12—74
35—65
45—70
25—70
46—65
I 8—74
34—56
25—74
40—65
20—59
14—16
40—74
46—65
MF
MF
F
M
MF
M
MF
MF
M
MF
MF
MF
F
MF
M
56
2,291
6,699
532
11,330
615
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that a threshold for dietary calcium intake exists at about 400to
500 mg per day, below which the prevalence of hypertension
can increase by about 25% [31, 50]. In a prospective study,
Witteman et al found approximately a 20% reduction in the
development of hypertension in women with a calcium intake
greater than 800 mg/day [51].
Collectively, these biochemical, nutritional, and clinical ob-
servations suggest that in settings where there is evidence of
failure to adequately regulate calcium homeostasis, hyperten-
sion is more likely to be present. These findings, however, do
not support a cause-and-effect relationship; a causal association
can be established only on the basis of clinical intervention
trials, animal investigations involving experimental models of
hypertension, and ultimately, cellular and subcellular experi-
ments that identify a mechanism or mechanisms.
Disturbances of calcium metabolism in animal models of
hypertension
Although our initial observations suggested that a relation-
ship exists between disturbed calcium metabolism and hyper-
tension in humans, we could not exclude the possibility that the
calcium abnormalities were only an epiphenomenon. Accord-
ingly, we turned to laboratory models of hypertension to
address several essential points. If investigations of animal
models of hypertension identified a biochemical pattern consis-
tent with altered calcium metabolism, then characterizing the
organs and cell types involved in the manifestation of these
disturbances of calcium metabolism might provide critical in-
sights into the mechanisms involved. Experiments in animal
models provide a controlled setting in which to determine
whether modifying dietary calcium intake changes blood pres-
sure. Furthermore, with animal studies it should be possible to
assess whether calcium's effect on blood pressure is a nonspe-
cific one observed only in certain forms of experimental hyper-
tension, or a more generic one, modifying the course of blood
pressure development in divergent models that share only one
common characteristic, altered vascular resistance.
The information that has accumulated on animal studies of
calcium and hypertension is characterized by remarkable con-
sistency in some areas and by apparent discrepancies in others.
The inconsistencies have been the subject of several analyses
[52, 53]; we recently reviewed the findings from most of the
reports and offered possible explanations for many of the earlier
inconsistencies [53].
Evidence of disturbed calcium homeostasis can be identified
in many experimental models of hypertension including the
male spontaneously hypertensive rat (SHR), the salt-sensitive
strain of the SHR [54], the Milan strain of the SHR [55], the
Dahi sodium-chloride-dependent genetic rat model [56, 57], the
DOCA-saline rat model (a mineralocorticoid/sodium-chloride-
dependent model) [56, 58], and the renal vascular rat model (the
"two-kidney, one-clip" rat model) [59]. In each instance,
evidence favoring disturbed calcium metabolism has been ad-
duced principally in the male.
Biochemical defects. The Aoki-Okamoto SHR displays a
variety of biochemical defects in calcium metabolism previ-
ously noted in humans [53]. These defects include elevated
circulating parathyroid hormone levels [60], which are evident
as early as 6 weeks of age [61]. Hyperactivity of the parathyroid
glands in these animals has been verified by a recent report by
Merke and colleagues, who observed an increase in parathyroid
gland mass in animals II weeks of age [62].
Serum ionized calcium values, with few exceptions, are
reduced by 5% to 7%; this finding is similar to that in humans
[53, 60, 63]. Serum phosphorus values are low and serum total
calcium values do not differ significantly from controls [60]. The
SHR has low circulating 1,25 dihydroxyvitamin D3 levels
which, in the setting of elevated P1'H and low serum ionized
calcium and phosphorus, is compelling evidence for a disregu-
lation of 1,25 dihydroxyvitamin D3 metabolism [64—66]. Ele-
vated calcitonin levels have been found in the 8-week-old [67]
and the 16-week-old SHR [68]. This finding supports the hy-
pothesis that the calcium-regulating hormone axis is disturbed
in the setting of experimental hypertension.
In young animals, urinary calcium excretion is normal or
lower in the SHR compared with the Wistar-Kyoto rat (WKY)
[67, 69]. From mid-adolescence (16—17 weeks of age) onward,
however, urinary calcium excretion is increased in the SHR
compared with the WKY [60]. Urinary cAMP excretion is
normal or slightly below normal in the SHR; with chronic
stimulation by parathyroid hormone infusion, the SHR appears
unable to sustain the same degree of urinary cAMP production
or calcium mobilization as the WKY [70].
Low serum ionized calcium values also have been found in
the DahI salt-sensitive, the DOCA-saline, and the two-kidney,
one-clip rat models [591; on average, the ionized serum calcium
level is 5% to 7% less in hypertensive rats than in normotensive
controls. Serum total calcium values do not differ from those in
normotensive animals [53, 59]. Urinary calcium excretion has
been reported as elevated compared with the control animal for
the Milan strain of the SHR [55], the DOCA-saline rat, and the
DahI sodium-chloride-dependent rat model [56].
The perturbations of calcium metabolism that are consistent
with a calcium deficiency are evident principally in the male
animal; an exception to this general statement is the increased
urinary calcium excretion (UcaV) and decreased serum ionized
calcium that occur in both sexes [53]. The female SHR does
exhibit abnormal parameters of calcium metabolism, but the
abnormalities are the obverse of those noted in males. This
contrast between sexes is similar to what is observed in humans
[71]. Furthermore, and potentially of critical importance, the
emergence of these biochemical defects appears to follow an
age-dependent pattern [53]. Parathyroid gland function is in-
creased and serum calcium decreased early in the life of the
SHR. Parathyroid hyperplasia has been demonstrated in the
Il-week-old SHR [62]. Not until later in life (15 to 20 weeks of
age), however, do consistent differences in UaV emerge.
Thus, age- and gender-dependent differences might account for
some of the discrepancies in the literature regarding the pres-
ence or absence of these biochemical abnormalities in the SHR
[52, 53].
Organ defects. Several defects related to either the regulation
of calcium homeostasis or organ responsiveness to the intracel-
lular calcium signal have been identified in experimental mod-
els. The SHR again has been the subject of the most intense
investigation, although several other animal models also have
been studied. The organs involved include the proximal duode-
num, kidney, bone, parathyroid glands, and vascular smooth
muscle.
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The status of calcium transport by the proximal duodenum in
hypertensive animal models is controversial. Multiple tech-
niques have been utilized to assess calcium handling by the
duodenum. Investigators have reported normal absorption as
well as increased or decreased calcium transport, not only using
different but sometimes the same techniques [53, 64, 72—79].
Studies utilizing only the male SHR and intact duodenal tissue
under controlled electrical conditions (Ussing chamber) consis-
tently have reported low levels of net intestinal calcium trans-
port (J,,) in 12-week-old rats [64, 74] and also in 24-week-old
rats fed a low-calcium diet [74]. Balance studies have suggested
abnormally high levels of absorption in the 4-week-old SHR [69,
78], but by the 12th week of age, absorption is lower in the SHR
than in the WKY [78]. These age-related differences in intesti-
nal calcium absorption are consistent with the hypothesis that
in experimental hypertension disturbances of calcium metabo-
lism evolve as the animal matures and hypertension emerges.
In the kidney, the important finding in the SHR is that 1,25
dihydroxyvitamin D3 synthesis [79] is decreased in conjunction
with increased urinary calcium clearance [80]. Bone studies
have identified a reduction in density and calcium content in the
male SHR (older than 24 weeks) [64, 81], with increased bone
density in females at one year of age [74]. Reduced bone density
has been reported in a recent study of the salt-sensitive DahI rat
[821. Reduced bone density is the ultimate evidence for a failure
of the hypertensive animal to retain an appropriate amount of
calcium.
In vascular smooth muscle, a variety of alterations related to
calcium metabolism have been reported, including altered sen-
sitivity to calcium-regulating hormones (Bukoski RD, unpub-
lished observations), increased membrane permeability to cal-
cium [83, 84], and greater dependence on extracellular calcium
for membrane stabilization [85].
In the Milan strain of SHR, decreased renal calcium reab-
sorption has been linked to a decrease in the renal epithelial cell
calcium ATPase activity [55]. Likewise, in the DOCA-saline rat
model and in the DahI sodium-chloride-dependent genetic
model, increases in urinary calcium excretion have been char-
acterized [56]. Failure to regulate calcium homeostasis is char-
acteristic of experimental hypertension even when the initiating
event may differ. An inability to absorb dietary calcium from
the intestine or reabsorb filtered Ca2 in the nephron appear to
be common threads in the link of disturbed calcium metabolism
to elevated arterial pressure. Since the normal maintenance of
calcium balance by these two organs is dependent on active
Ca2 transport, the implications for a cellular defect in such a
primary process is evident.
Defects in cell calcium metabolism. Cellular calcium-han-
dling defects have been identified in experimental models of
hypertension, principally in the SHR. Of greatest importance is
the multitude of abnormalities described in the vascular smooth
muscle cell isolated from the SHR [53]. The presence of
potentially important defects of cell regulation in several cell
types suggests, at least in the genetic model of the SHR, that a
fundamental disturbance in either calcium binding or calcium
transport is programmed into the cells. Of particular note are
the observations that enterocyte influx [86] and efflux [87] of
calcium are reduced in the SHR and that renal intracellular
calcium may be elevated [88]. This latter finding might account
for the alterations in 1,25 dihydroxyvitamin D3 production by
the proximal renal tubular cell and for the impairment of
intestinal calcium transport. Other investigators, however,
have found either no differences or a decrease in renal tubular
intracellular free calcium [89, 90]. Probably of less importance
in the pathophysiology of hypertension are the observations in
the SHR that intracellular calcium may be elevated and/or that
membrane-bound calcium may be decreased in red cells [91],
lymphocytes [92], and platelets [93]. These observations do
suggest, however, that a generalized alteration in the regulation
of intracellular calcium metabolism in this particular model of
experimental hypertension does exist.
Intracellular calcium disturbances. As I noted, several inves-
tigators have reported increases in intracellular free calcium (as
measured by calcium-sensitive dyes) in platelets, lymphocytes,
and proximal tubular cells of the SHR. Recent studies have
used the more sensitive fura-2 calcium indicator. This technique
makes it possible to study intact resistance vessels and to
measure intracellular calcium both in vascular tissue, where the
endothelial layer is intact, and in isolated, cultured, single
vascular smooth muscle cells. Using the fura-2 technique on
cultured vascular smooth muscle cells isolated from the SHR,
we have not been able to identify an increase in basal intracel-
lular free calcium [94]. In isolated mesenteric resistance vessels
from the SHR and WKY, Bukoski found decreased calcium
transients in vascular tissue derived from the hypertensive
animals as compared with normotensive controls (unpublished
observations). The finding of normal basal levels and a de-
creased calcium transient in the vascular tissue of the SHR is in
direct opposition to the increase in intracellular free calcium of
vascular tissue, as originally hypothesized by Blaustein [10].
Calcium fluxes have been measured in vascular smooth
muscle cells [95] and in isolated duodenal enterocytes of the
SHR [86]. In smooth muscle cells, influx is increased; in
enterocytes, precisely the opposite has been observed. Ente-
rocytes exhibit not only a low influx rate, but a diminished
intracellular calcium pool (both bound and free). Calcium efflux
rate constants also are decreased in SHR enterocytes, probably
as a functional response to the decrease in the calcium influx
rate [87]. The differences in measured Ca2 influx between
these two cell types likely reflect the fundamental variations in
the techniques used in these experiments and do not necessarily
indicate opposite effects in these two systems. Both could
reflect a defect in the intracellular transport of calcium.
Magnesium-calcium-ATPase pump activity is decreased in
the vascular tissue of the SHR [96]. The observation that
calcium uptake by vesicles from isolated vascular smooth
muscle is decreased in the SHR led to the assumption that this
decrease reflects an abnormality of the calcium pump. Calmo-
dulin activity has been studied in the brain of the SHR [97].
Compared with the WKY control, no differences exist in the
activation of the protein by calcium or in its ability to stimulate
phosphodiesterase activity. However, Nojima, Kishi, and So-
kabe identified a pseudocalmodulin protein in the brain of the
SHR that exhibits an amino-acid-sequence defect in one of the
four critical calcium-binding regions of the calmodulin molecule
[98]. Calcium-binding-protein content is reduced in renal and
duodenal cells isolated from the SHR [78]. The integral mem-
brane calcium-binding protein (IMCAL) also has been reported
to be decreased in the enterocytes of SHR [99]. Huang and
colleagues recently reported increased levels of an activator of
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Fig. 2. Schematic portrayal of the various
defects of cell calcium metabolism reported in
hypertensive humans and experimental
models. (RBC, red blood cell; VSM, vascular
smooth muscle.)
Fig. 3. Schematic description of the
relationships among a defect in cell calcium
transport, renal reabsorption of calcium,
intestinal calcium absorption, vascular
smooth muscle calcium handling, and the
development of hypertension.
calmodulin in the heart, kidney, and vascular tissue of the SHR
[100].
These observations point to important cellular calcium de-
fects in experimental hypertension (Fig. 2). These defects could
represent multiple disturbances in different cell lines or might
reflect an effect of a single, primary defect in the regulation of
the calcium pump by either calcium or calmodulin, in the
binding of calcium to its critical intracellular binding protein, or
in the response to a local circulating factor that activates
calmodulin. Such a defect or defects in vascular tissue could
result in either increased reactivity or abnormal cell growth,
either one of which would cause peripheral resistance to rise
and arterial pressure to be elevated. Much additional investiga-
tive work is needed to clarify the issues surrounding the
pathophysiology of disturbed cellular calcium metabolism that
is associated with elevated arterial pressure.
Figure 3 provides a theoretical depiction of the way in which
data from studies of human and experimental hypertension
might be tied together. This schema suggests that afflicted
individuals might encounter a problem in the presence of
reduced dietary calcium intake because of a simultaneous
impairment in their ability to retain calcium. One could hypoth-
esize that, either because of a genetic defect or an acquired
effect stemming from inadequate intake of calcium itself, a
disorder of cell calcium transport appears to develop that
produces submaximal intestinal absorption and inadequate re-
nal reabsorption of calcium. As a consequence, the alteration in
biochemical parameters portrayed in Figure 3 would occur, and
retained calcium (and thus bone density) would be reduced. In
the vascular smooth muscle cell, fundamental shifts in cell
calcium permeability, transport, storage, and release might
develop that potentially would modify optimal vascular smooth
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muscle function and result in an increase in peripheral resis-
tance and arterial pressure through subcellular mechanisms that
remain to be determined.
Blood pressure response to increased calcium intake
Experimental studies. The antihypertensive effect of in-
creased dietary calcium has been studied in five hypertensive
models and in several normotensive strains. Animals that are
responsive to increased dietary calcium intake include the
following models: SHR [60, 61, 101], salt-sensitive SHR (Ta-
conic Farms) [54], DOCA-saline rat model [102, 103], DahI
sodium-chloride-dependent genetic model [104], and the two-
kidney, one-clip renovascular model [105]. In addition, in-
creased dietary calcium also lowers blood pressure in normo-
tensive rats including the WKY [106], Wistar [107], and Fischer
344 strains [108]. Several studies also have examined the effects
of calcium restriction on blood pressure [60, 106]. The calcium
content of a standard rat diet is considered to be 0.8% to 1.0%
by weight. Our initial studies showed a reduction in blood
pressure when we fed rats a high-calcium (4%) diet [60]. We
subsequently used a less elevated level of dietary calcium,
approximately 2%, and documented a similar blood-pressure-
lowering effect [74, 109]. Karanja et al from our laboratory
recently reported a dose-response curve for dietary calcium in
the SHR; 90% of the antihypertensive effect was reached with
a diet of 1.5%; only a minimal further reduction in blood
pressure was achieved at higher dietary calcium levels [1091.
Thus, the inverse relationship between dietary calcium content
and blood pressure is nonlinear in the SHR as it is in humans
[29, 48]. In the male SHR, the steepest portion of this curve lies
between 0.25% and 0.5% dietary calcium [109]. Within this
range the greatest change in blood pressure of the SHR will
occur. We have not been able to identify a consistent antihy-
pertensive effect in the female SHR, although a decrease in
blood pressure was reported by Lau and coworkers [1101.
Hatton and colleagues demonstrated an effect of reduced
maternal calcium intake on the fetus and during the first 3 weeks
postpartum [111]. These manipulations significantly affected the
development of hypertension in the young SHR: besides the
dose dependency, a time dependency of calcium's antihyper-
tensive effect has been identified. When the diet of the very
young animal is supplemented with calcium, the antihyperten-
sive effects emerge more rapidly. If supplemental calcium is
introduced during adolescence, a longer period (up to 10 weeks)
may be necessary for an antihypertensive effect to emerge.
Calcium's effect on blood pressure in the SHR is influenced
importantly by the accompanying level of sodium intake. So-
dium restriction impairs the antihypertensive effect of increased
dietary calcium, whereas modest sodium supplementation en-
hances calcium's antihypertensive action [74]. Of the various
calcium salts studied, the carbonate has been used most com-
monly; however, calcium phosphate [107], lactate, gluconate,
citrate, and chloride [112] also lower blood pressure in experi-
mental models.
The rise in blood pressure typically observed in the DahI
sodium-chloride-dependent genetic model of hypertension is
prevented by providing a 2% calcium diet [101]. In the DOCA-
saline model of experimental hypertension, supplemental cal-
cium also prevents the rise in blood pressure typically induced
by a high sodium-chloride intake and by administration of
mineralocorticoids [102, 1031. Similarly, in the renovascular
model (the two-kidney, one-clip hypertensive rat), calcium
supplementation over a relatively short period (4 to 6 weeks)
prevents blood pressure from rising [105]. Furthermore, sup-
plementing the diet with calcium reverses a number of the
hormonal changes characteristic of this model [60, 61]. The
blood pressure in the salt-sensitive SHR does not rise when the
sodium chloride content of the diet is increased, if calcium is
also added to the diet [54]. Not only does supplemental calcium
result in normal blood pressure regulation in this model, but the
defects in central nervous system regulation of blood pressure
noted by previous workers are prevented by this intervention
[54].
These observations from hypertensive and normotensive
animals, in which genetic backgrounds differ, and in which the
primary pathophysiologic mechanisms vary widely, suggest
that calcium lowers blood pressure by a generic action. Periph-
eral vascular resistance is increased in all these models, and
increasing calcium intake lowers blood pressure in each case. It
is reasonable to suggest, therefore, that dietary calcium either
has a salutary effect on circulating factors that control periph-
eral vascular tone, or that it has a direct effect on the response
of vascular smooth muscle cells to circulating factors. An
additional possibility is that the dietary calcium corrects a
primary defect in intracellular calcium metabolism. How in-
creasing dietary calcium might reverse such a cellular defect is
a matter for speculation.
Human studies. Whereas epidemiologic studies have demon-
strated that dietary calcium intake is lower in humans with
hypertension than in normal individuals and that many hyper-
tensive patients exhibit biochemical and metabolic evidence of
calcium depletion, the critical test of the hypothesis that failure
to maintain a net positive calcium balance will result in an
increase in blood pressure is whether changes in dietary cal-
cium intake influence blood pressure. Although animal studies
suggest that modification of dietary calcium changes blood
pressure, the clinical relevance of these observations ultimately
depends on whether similar findings are documented in con-
trolled clinical studies. Table 2 summarizes the 20 trials of
calcium supplementation that have been published or presented
at scientific meetings to date [16, 38, 113—129]. Three of these
trials were not properly controlled with a placebo phase or a
control group, but 13 included both random patient allocations
and a placebo control group. The level of calcium supplemen-
tation employed in the various studies ranged from 0.4 to 2.0
glday and most commonly were 1.0 to 1.5 g/day. Most studies
used calcium carbonate, but some used calcium citrate, gluco-
nate, or lactogluconate, and one used yeast; in 2, a dietary
source of calcium was employed. The length of supplementa-
tion ranged from 5 days to 1 year.
Blood pressure fell significantly in at least a subset of the
population studied in three-quarters of these trials; no signifi-
cant blood pressure changes were reported in the other one-
fourth. In no study was a significant increase in blood pressure
detected for the population under observation. Blood pressure
reductions with calcium supplementation ranged from 2 mm Hg
to 10 mm Hg, with a median of 5 mm Hg. The studies reporting
the most convincing blood pressure reductions involved ran-
dom patient allocation, a placebo control period, and larger
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Table 2. Survey of studies of calcium supplementation and blood pressure (BP)
—-
Subjects SignificantBP
Author No. Age Design Dose of calcium response
Belizan, 1983 [1131
Resnick, 1983 [1141
Johnson, 1985 [381
McCarron, 1985 [161
Morris, 1985 11151
Meese, 1986 11161
Grobbee, 1986 11171
Luft, 1986 [118]
Tabuchi, 1986 11191
Morris (unpublished)
Bloomfield, 1986 [1201
Lyle, 1987 11211
Strazzullo, 1986 [122]
Bierenbaum, 1987 [123]
Gilliland, 1987 [1241
Thomsen, 1987 [125]
Vinson, 1987 [126]
Cappuccio, 1987 [127]
Morris, 1987 [128]
Van Beresteyn, 1986 [129]
57
10
95
80
16
27
90
16
8
86
32
75
17
200
24
28
15
18
133
58
18—35
—
35—65, F
22—70
30—65
—
18—27
22—56
= 73
50—80
18—75
19—52, M
= 43,
M
2 1—56
57±10
—. F
19—24, M
28—65
18—70
20—23, F
Randomized, placebo
Uncontrolled
Placebo
Randomized, crossover,
placebo
Randomized
Randomized, crossover,
placebo
Randomized, placebo
Randomized, crossover,
placebo
Placebo
Placebo
Randomized, placebo
Randomized, placebo
Randomized crossover,
placebo
Uncontrolled
Uncontrolled
Randomized, placebo
Randomized, placebo
Randomized, placebo
Randomized, placebo
Randomized, placebo
I g (CaCO3) X 22 wk
2 g (CaCO3) x 5 days
1.5 g (CaCO, citrate) x 8 wk
I g (CaCO3, citrate) X 8 wk
I g (CaCO, citrate) x 16 wk
800mg (Ca2', citrate) x 8 wk
I g (CaCO3) x 12 wk
I g (CaCo3) x 8 days
2 g (gluconate) x 2 wk
I g (CaCO3) x 12 wk
1.5 g (CaCO1) x 4 wk
1.5 g (CaCO3) x 12 wk
1 g (lactogluconate + carbonate) x 15 wk
1.4 g (milk) x 6 mo
400 mg (CaCO3) x 24 wk
2000 mg x I yr
500 mg (Ca gluconate) or 500 mg (Ca yeast) x 7
wk
1600 mg/day (Ca lactate glucose) x 4 wk
1.0 g (CaCO3) or 1.5 g (dietary Ca) X 12 wk
1500 mg (CaCO3 powder) X 6 wk on Ca-restricted
diet (500 mg/day)
Yes
Yes
Yes
Yes
Yes
No
Yes
Yes
Yes
Yes
No
Yes
Yes
Yes
Yes
No
Yes
No
Yes
No
study populations. All the studies reporting no significant blood
pressure change, however, typically employed small sample
sizes (approximately 10 to 15 per treatment group). Thus, the
"negative" results of these studies might have been the result
of sample sizes too small to detect the modest reductions in a
population's blood pressure observed with calcium supplemen-
tation.
Of the studies that did detect a blood pressure reduction, all
but 2 used at least 8 weeks of supplementation. By contrast, 2
negative trials, one by Bloomfield [120] and one by Cappuccio
[127], used calcium supplements for only 4 weeks. Two of the
positive trials were also of short duration (1 to 2 weeks), but
significant blood pressure reductions probably were detected in
these studies either because of a relatively high level of supple-
mentation [113] or because of intense observation in a meta-
bolic ward of a hospital [1181.
Supplementing the diet with calcium has been reported to
reduce blood pressure both in hypertensive and normotensive
populations. With the exception of the report by Tabuchi [119],
studies of hypertensives have, for the most part, focused on
individuals with borderline to mild hypertension. Not surpris-
ingly, somewhat greater blood pressure reductions have been
achieved in hypertensive than in normotensive populations.
Although blood pressure falls with increased calcium intake in
both sexes, males experience somewhat greater reductions
[128]. Two of the best-controlled and largest trials enrolled
either males alone [1211 or predominantly males [117]; blood
pressure was lowered in the calcium-supplemented (versus
placebo control) group by 2.8 mm Hg systolic and 2.3 mm Hg
diastolic in one and by 3.1 mm Hg diastolic in the other. These
studies are particularly important because of the absence of
adverse reactions to the calcium supplements and for the lack of
patient dropout due to side effects. It is noteworthy that no
study subject has been reported as having developed renal
calculi during calcium supplementation.
Although the reductions in blood pressure observed in these
clinical trials have been modest (3 mm Hg to 6 mm Hg), such
changes, extrapolated to the general population, could yield
significant benefits with respect to overall cardiovascular mor-
bidity and mortality [130]. Moreover, the modest reductions
represent average changes in blood pressure and include some
individuals who experienced a fall in systolic blood pressure of
greater than 20 mm Hg compared with values recorded during
placebo control [16]. Similarly, as with most antihypertensive
interventions, some individuals have no apparent response to
the treatment and some sustain a rise in blood pressure [16,
126]. This heterogeneous response to calcium supplementation
is similar to that observed in clinical trials of sodium restriction
[131—133] and potassium supplementation [134].
Predictors of a blood pressure response in humans
Many parameters have been analyzed in an effort to predict
who will have a beneficial response to calcium supplementa-
tion. As I said, males appear to be slightly more responsive than
are females, particularly males who are normotensive to start
with, although this difference is not firmly established. In one
trial that had ample numbers of black and white subjects, no
difference in blood pressure response was found between the
two races [121]. Ethnic origin similarly does not appear to be a
predictor of response.
Among various biochemical parameters, serum ionized cal-
cium has not been a predictor of a favorable blood pressure
response, although in our initial trial the individuals who
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Fig. 4. Theoretical mechanisms by which
modification of dietary calcium intake might
alter vascular smooth muscle function and
arterial pressure.
experienced the smallest change in ionized calcium also had the
largest drop in blood pressure [16]. Resnick et al reported that
patients with low-renin hypertension have the most notable
response. In this subgroup, these investigators found relatively
low levels of serum ionized calcium [20]. Some patients with
high-renin hypertension experience a minimal pressor effect
[114]. Grobbee and Hofman reported that subjects whose serum
total calcium level was below the median had a greater blood
pressure response compared with those whose levels were
above the median [117]. Similarly, people who were above the
median for parathyroid hormone level had greater reductions in
blood pressure.
We have been unable to identify a predictive value for
circulating serum 1,25 dihydroxyvitamin D3 levels (Morris CD,
personal communication), and we were unable to verify the
predictive value of plasma renin status reported by Resnick et al
[20, 135]. In our experience, urinary calcium excretion has not
been a predictor of blood pressure response [16]; however,
Strazzullo et al did find a correlation between urinary calcium
excretion during the placebo phase and a greater blood pressure
reduction with calcium supplementation [122]. Finally, baseline
dietary calcium intake has not been predictive of a blood
pressure response in any of our clinical trials [16, 115, 128].
Grobbee et a! reported that parathyroid hormone and total
serum calcium levels might be modestly predictive of a blood
pressure response [1171. The predictive value, however, is not
of sufficient magnitude to enable the clinician to identify indi-
vidual patients who might benefit.
Mechanisms ofaction
Several potential mechanisms have been postulated to ex-
plain how dietary calcium affects blood pressure. Figure 4
represents a number of these mechanisms. I principally will
focus on the ways in which dietary calcium might affect the
intrinsic properties of the resistance arterioles or circulating
factors that modify vascular smooth muscle contractility. I also
will discuss briefly several nonvascular mechanisms.
Vascular smooth muscle. Early work by Bohr et al [136]
prompted us to postulate a membrane-stabilizing effect of
dietary calcium that would reduce vascular sensitivity to circu-
lating vasoconstrictors [28]. This postulate was subsequently
tested in our laboratory [137, 138]. No consistent alteration in
the sensitivity of either aortic or mesenteric vascular rings to
exogenous norepinephrine was identified in animals fed a
calcium-supplemented diet. In the course of those studies, we
also assessed whether dietary calcium impairs maximal con-
tractility of the vasculature; such an effect also might result in a
lowering of blood pressure. These studies have demonstrated
that quite the reverse is true. In the SHR, calcium supplemen-
tation produces an increase in maximal contractility, thereby
reversing the impaired maximal contractility in this model.
Using isolated, cultured, aortic vascular smooth muscle cells
from the WKY and SHR, we assessed the effect of long-term
exposure to increased extracellular calcium within the physio-
logic range on cell 45Ca2 uptake [139]. Prolonged exposure to
higher extracellular calcium produces a greater 45Ca uptake of
the isolated vascular smooth muscle cells from the SHR. No
effect was observed in the WKY. More recently, we assessed
prostacyclin production by aortic rings isolated from SHR fed a
calcium-supplemented diet from 3 to 12 weeks of age [140].
Compared with animals maintained on low-calcium diets, the
vascular tissue of the calcium-supplemented animals exhibited
a significant increase in production of 6-keto-PGF1,, an indica-
tion that production of this vasodilator, prostacyclin, was
increased by the vascular tissue.
Passive properties of the vascular smooth muscle also must
be considered. Vascular smooth muscle hypertrophy long has
been known to develop in the hypertensive animal in concert
with a rise in blood pressure 1141]. The SHR's vascular smooth
muscle cells proliferate faster than do those of the WKY. No
data regarding the effects of calcium supplementation on cell
growth and hypertrophy are available, however. Passive elastic
properties of the vasculature also contribute to blood pressure
regulation, particularly basal blood pressure. Vascular aortic
rings isolated from the calcium-supplemented SHR exhibit an
improvement in passive-elastic properties [137]. The calcium-
supplemented animal does not experience the typical age-
related reduction in vessel compliance. This effect on vessel
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compliance might not only explain reductions in basal blood
pressures, but could prove important in the progression of
vascular disease if similar beneficial effects on compliance are
documented in resistance vessels. These observations suggest
several possible mechanisms, although it is premature to draw
any conclusions about how dietary calcium might act on vas-
cular smooth muscle to lower arterial pressure.
Calcium-regulatinghormone. Vascular tissue contains recep-
tors for PTH and l,25(OH)2 vitamin D [142, 143], and circulat-
ing levels of both these hormones are modified by changes in
dietary calcium intake. Thus, calcium-regulating hormones
must be considered potentially important mediators of dietary
calcium's antihypertensive effect 1135, 144]. Recent studies in
our laboratory have demonstrated a direct effect on calcium
regulation in vascular smooth muscle cells by both of these
calcium-regulating hormones [144]. The incubation of isolated
vascular smooth muscle cells with either parathyroid hormone
or vitamin D stimulates 45Ca2 uptake [139]. Of possibly greater
importance is the observation that short-term incubation of
intact mesenteric resistance vessels with either I ,25(OH), vita-
min D3 or PTH significantly modifies the calcium transient (as
measured by fura-2) evoked by exposure to norepinephrine
(Bukoski RD, personal communication). In vessels from nor-
motensive animals, 1,25 dihydroxyvitamin D5 dampens the
calcium transient and increases the transient in vessels isolated
from the SHR. Likewise, PTH reduces the calcium transient in
the WKY, but exhibits only minimal effects on the calcium
transient in the SHR.
These findings suggest a direct intracellular effect of the
calcium-regulating hormones on calcium release and possibly
storage by intact resistance vessels and/or cultured vascular
smooth muscle cells derived from experimental animals. The
data further suggest that the observed response to the calcium-
regulating hormones differs based on whether the vascular
tissue is isolated from hypertensive or from normal animals.
The mechanisms by which 1,25(OH), vitamin D3 and PTH
modify cellular calcium uptake or calcium transients are un-
known. A vasodilatory action of parathyroid hormone has long
been recognized [145—147], The observations I have noted in
isolated vascular tissue along with the identification of PTH
receptors in vascular tissue represent the first evidence that
PTH's effects on blood pressure might be mediated through a
direct action on the intracellular handling of calcium by resis-
tance vessels.
Central-nervous-syste,n effects. Several lines of evidence
suggest that dietary calcium supplementation modifies central-
nervous-system sympathetic outflow [148. 149]. Hatton and
colleagues demonstrated that both acute [148] and chronic
stress-induced elevations [149] in blood pressure were damp-
ened by dietary calcium supplementation in the SHR. Likewise,
Yang and coworkers reported that the alterations in central-
nervous-system response to sodium-chloride loading in the
salt-sensitive SHR are obviated by dietary calcium supplemen-
tation [54]. Finally, Peuler et al demonstrated in the DahI
salt-sensitive rat that calcium supplementation reduces sympa-
thetic outflow concurrent with a reduction in blood pressure
[104]. Scrogin and coworkers measured peripheral catechol-
amine levels in the calcium-loaded SHR and observed that
circulating catecholamine levels are, if anything, slightly ele-
vated on the higher-calcium diets 1150]. This finding must be
reconciled with the observation that central-nervous-system
sympathetic outflow is reduced following dietary calcium sup-
plementation in the salt-sensitive SHR and DahI rats [54, 104].
Scrogin et al suggested that calcium loading affects catechol-
amine-receptor binding in vascular tissue without necessarily
altering peripheral catecholamine release [150].
Phosphate depletion. Lau and colleagues proposed that phos-
phate depletion, induced by a high calcium intake, impairs
cardiac and vascular contractility, thereby accounting for the
hypotensive effects of dietary calcium [151]. Although neither
changes in phosphate balance nor intracellular phosphate-
dependent energetics have been assessed thoroughly, several
lines of evidence argue against this theory. First, at levels of
supplemental calcium in the relatively low range of 2%, serum
phosphorus concentrations, although lower than control, re-
main well within the normal range and are not consistent with
the degree of hypophosphatemia typically associated with im-
paired cardiovascular response [74]. Second, the observation
that maximal vascular contractility is improved in the vascular
tissue of the calcium-supplemented hypertensive animal indi-
cates that vascular smooth-muscle contraction is not dimin-
ished on a high-calcium diet [137]. Third, Bindels et al demon-
strated that dietary phosphate supplements in the SHR reduce
blood pressure during mid-adolescence [1521. This last obser-
vation runs contrary to the notion that phosphate depletion
accounts for the blood-pressure-lowering effects of dietary
calcium. Nevertheless, given the critical role of dietary phos-
phorus in modulating calcium homeostasis as well as the
synthesis and release of a number of the calcium-regulating
hormones, the role of phosphate metabolism requires further
study.
Nonvascular mechanisms. Nonvascular mechanisms for the
antihypertensive effects of dietary calcium also must be consid-
ered. First, a reduction in intravascular volume as a conse-
quence of a natriuretic action of calcium supplementation has
been proposed and is based on observations by several groups
[2, 61]. This hypothesis has been addressed directly in humans
by Luft and coworkers, who were unable to demonstrate any
change in sodium balance in a metabolic study of normal
individuals and hypertensive patients whose diets were supple-
mented with calcium for one to two weeks [118]. Second, Lau
et al observed that vascular volume is increased in the calcium-
supplemented SHR in which blood pressure has been reduced
[151]. In younger animals fed additional calcium, Hatton et al
found no change in plasma volume [153]. The most compelling
evidence against a significant natriuretic action of calcium
comes from two reports that indicate that calcium's antihyper-
tensive action is enhanced by simultaneous sodium chloride
supplementation [74, 154]. Collectively, these observations
strongly argue against a reduction in intravascular volume, and
thereby overall sodium balance, being induced by calcium
supplementation.
A change in blood viscosity is another nonvascular mecha-
nism by which dietary calcium might affect blood pressure.
Hatton and colleagues measured changes in hematocrit that
occur with calcium supplementation as an indirect assessment
of viscosity [155]. The changes in blood pressure observed with
the higher calcium intake were independent of changes in the
animal's hematocrit.
Thus, central as well as peripheral mechanisms appear to be
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involved in the blood pressure reduction noted with calcium
supplementation. The central mechanisms might include a
reduction in central sympathetic outflow; the peripheral mech-
anisms could reflect changes in circulating calcium-regulating
hormones that appear to have dirtct vascular actions. Calcium
supplementation probably affects calcium metabolism in vascu-
lar smooth muscle and also might alter passive-elastic proper-
ties of vascular smooth muscle. Finally, changes in prosta-
glandin metabolism suggest that membrane phospholipid
metabolism is another potentially productive area for further
investigation of the mechanisms of dietary calcium's blood-
pressure-lowering effect.
Potential areas of clinical application
The relationship of dietary calcium to blood pressure might
be particularly pertinent to several subpopulations at risk of
developing hypertensive cardiovascular disease. Kurtz and
coworkers demonstrated that sodium-chloride-sensitive hyper-
tensive men manifest increased urinary calcium excretion [156],
reminiscent of the hypercalciuria observed in the DOCA-saline
and DahI sodium-chloride-dependent experimental models [57].
The observation that calcium supplementation lowers blood
pressure in various animal models of sodium-chloride-related
hypertension [102, 104] should encourage further exploration of
the link between calcium homeostasis and sodium chloride
sensitivity in human hypertension.
Pregnancy-induced hypertension is another important clinical
problem for which the concepts outlined in this review could
have future application. Several disturbances of calcium metab-
olism, some similar to those observed in essential hypertension,
have been identified in pregnant women [157—159]. Further-
more, several intervention trials already have demonstrated
that during the third trimester of pregnancy calcium supplemen-
tation significantly reduces the incidence of pregnancy-induced
hypertension [160—162].
Hypertension is common in type-Il diabetes mellitus, and a
number of the calcium disturbances associated with essential
hypertension also have been described in this disorder
[163—165]. Gaboury et al [166] and Mondon and Reaven [167]
recently reported that the spontaneously hypertensive rat (the
best-characterized experimental model of calcium-mediated
hypertension) also exhibits biochemical and humoral character-
istics consistent with type-Il or insulin-resistant diabetes. Per-
shadsingh and Kurtz also have provided a theoretical patho-
physiologic association between the increased insulin levels
observed in hypertensives and cellular calcium metabolism
[168].
Alcohol-associated hypertension offers yet another provoca-
tive example of an association worth exploring. Chronic alcohol
ingestion induces several alterations in cell calcium homeosta-
sis [169, 170] and ultimately results in significant bone mineral
loss [1711. An interaction among alcohol consumption, dietary
calcium intake, and blood pressure has been reported in two
epidemiologic studies [34, 39]. In addition, Criqui et al reported
that, compared with other relationships between nutrients and
blood pressure, the association of dietary calcium to blood
pressure was evident only at low levels ofalcohol intake. Their
findings suggest a unique influence of alcohol on the way in
which dietary calcium affects blood pressure [172].
Systolic hypertension in the elderly may be another clinical
setting of interest. Dietary calcium intake declines significantly
with age [36]. Age-related abnormalities in calcium metabolism
parallel changes observed in hypertensive patients [173—175].In
a current trial in which we are assessing the effects of calcium
supplementation on blood pressure in older individuals, we
have observed potentially important age-related blood pressure
reductions [176].
Alterations in calcium metabolism may be particularly impor-
tant for the pathogenesis of hypertension in blacks. Dietary
calcium intake among blacks in the United States is significantly
less than that observed among whites [46, 47]. One epidemio-
logic study demonstrated that differences in dietary calcium
intake account for most of the variation in blood pressure
between adolescent white and adolescent black females [461.
Perhaps the most important implication of the hypothesis that
maintaining a net positive calcium balance will protect against
the development of hypertension is the demonstration that
maintenance of the recommended daily allowance for cal-
cium—the 800 to 1000 mg/day suggested by the U.S. National
Academy of Sciences—will prevent the blood pressure increase
that occurs with age in industrialized societies, and the atten-
dant premature morbidity and mortality. The frospective data
from Witteman et al [49], and the blood pressure reductions
achieved in some of the normotensive individuals studied in the
intervention trials, suggest that increasing dietary calcium in-
take can attenuate the rise in blood presstlte and reduce the
prevalence of hypertension that emerges with aging. This may
be particularly true in groups with chronic underconsumption of
dietary calcium, such as women and blacks.
Summary
Returning to the patient presented today, perhaps we can
now understand some of his findings. As I noted, men are more
likely to demonstrate alterations in calcium metabolism associ-
ated with elevations in blood pressure. Furthermore, blacks are
more likely than whites to develop hyperparathyroidism [177],
particularly in the third and fourth decades of life. It is unlikely,
however, that parathyroid hormone was responsible for the
increase in this patient's arterial pressure because PTH has a
vasodilating action. Moreover, the long-term response to para-
thyroidectomy is more likely to be an increase rather than a
decrease in blood pressure [1781. It is also unlikely that the mild
elevations in the serum total calcium observed in this patient
were responsible for his hypertension. Correction of hypercal-
cemia by surgical intervention failed to improve the blood
pressure. There is little evidence that mild, protracted hyper-
calcemia can account for increases in arterial pressure. Finally,
the patient's alcohol abuse might have contributed to his
elevated blood pressure; it is possible that his hypertension was
in part a reflection of the abnormal calcium metabolism he
developed as a consequence of the alcohol abuse.
Answers to some questions we faced when we first studied
this patient more than a decade ago can be provided by the
wealth of basic research and clinical investigation that has
occurred since. We now know that calcium metabolism is a
factor in blood pressure regulation in some humans and in some
experimental models. Epidemiologic studies document a con-
sistent association between lower dietary calcium intake and
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higher blood pressures in humans. An additional non-pharma-
cologic approach has been identified that can produce a modest
but important lowering of blood pressure in a subset of hyper-
tensive individuals. Much data show that calcium-regulating
hormones have important cardiovascular actions that might
account for some of the mechanisms by which increased dietary
calcium lowers blood pressure. Research in this area also has
set the stage for exploring another theoretical mechanism for
sodium-chloride-sensitive hypertension. Finally, a theoretical
mechanism(s) has emerged that could provide a pathophysio-
logic link between hypertension and certain high-risk popula-
tions such as blacks, the elderly, type-Il diabetics, and pregnant
women.
The principal clinical implication derived from this work to
date is the following: In patients with mild to moderate hyper-
tension, the level of dietary calcium intake should be assessed.
Patients whose intake is deficient should be encouraged simply
to maintain calcium intake at 800 to 1000 mg/day. Our challenge
is to attempt to prevent calcium deficiency in patients with
essential hypertension. We need not at this time strive to
increase dietary calcium to a level greater than the current
recommended daily allowance of the National Academy of
Sciences [3, 29].
Questions and answers
DR. MARSHALL LINDHEIMER (Renal Section, Mitchell Hos-
pital, Chicago, Illinois): If I understand correctly, females
appear to be more resistant than are males to the antihyperten-
sive action of supplemental calcium, and further, women dis-
play less frequent abnormalities in parathyroid hormone and
urinary calcium excretion when hypertensive. But you noted
that pregnancy-induced hypertension was one condition in
which calcium might prove therapeutic, because the data sug-
gest that hypocalciuria accompanies pre-eclampsia, and cal-
cium supplementation may decrease blood pressure in normo-
tensive gravidas. Why does pregnancy make a woman's
vasculature respond as if it were a man's?
DR. MCCARRON: In general, younger females are less likely
to exhibit a relationship between calcium metabolism and blood
pressure. This is not an absolute, however, because in some
premenopausal hypertensive women, the blood pressure falls
when calcium intake is increased [161. The pregnant female,
especially if she is black, appears to be an exception, particu-
larly at the extremes of the reproductive years. Based on
HANES I and II data, younger females in this country on
average have dietary calcium intakes in the range of 300 to 500
mg/day [29]. During the second and particularly the third
trimesters of pregnancy, significant metabolic demands are
placed on the pregnant subject's calcium-regulating system.
These demands reflect the calcium needed to mineralize the
fetal skeleton and to provide for fetal growth in utero. Dietary
calcium requirements during pregnancy and lactation have been
estimated as exceeding 1500 mg/day [179]. If dietary calcium
intake is significantly below this level, calcium depletion is
likely to develop in the pregnant individual. As I discussed,
blood pressure increases either as a direct reponse of the
vasculature or as a reflection of the cardiovascular responses to
increases in parathyroid hormone and vitamin D. Not enough is
known for me to be more specific. However, from the interven-
tion studies published to date, it is evident that increasing
calcium intake during pregnancy can lower the risk of develop-
ing gestational hypertension or pregnancy-induced hyperten-
sion [160, 180].
DR. GARY TOBACK (Renal Section, Mitchell Hospital): A
simple hypothesis that might explain some of the information
you presented is that in males who develop hypertension when
subjected to a low-calcium diet, a sex-specific trait—perhaps
related to an abnormal locus on the Y chromosome—accounts
for the high blood pressure. Has a double-blind study been
carried out on this set of patients to determine whether their
elevated blood pressure is alleviated by treatment with a
calcium-supplemented diet? Can hypertension be made to re-
appear in such patients by a return to the low-calcium diet? Do
males who develop hypertension on a low-calcium diet differ in
any way from males or females who do not develop hyperten-
sion on that diet? Is the natural history of the hypertension
induced in males by a low-calcium diet different from that
observed in other types of secondary hypertension?
DR. MCCARRON: Dr. Eric Young in our group at Oregon has
metabolic studies underway that attempt to characterize the
differences between the calcium-sensitive and calcium-insensi-
tive patients. I might also note that distinguishing a nutritional
factor from a genetic factor in a human population can be
difficult because nutritional patterns are passed along in a
family. We tend to eat as our parents do. If one doesn't keep
this difficulty in mind, lifestyle behavior could be mistaken for
a genetic trait.
DR. DAVID BUSHINSKY (Renal Section, Mitchell Hospital):
Serum total calcium tends to be high in hypertensive patients,
yet ionized calcium is low. This finding would imply an altera-
tion in calcium binding and suggests an abnormality in albumin
or another circulating protein. Has such an abnormality been
described?
DR. MCCARRON: In our experience, the correlation of higher
total serum calcium concentrations with higher blood pressure
is found primarily in females. Why this gender difference exists
for total serum calcium values is not known. The serum ionized
calcium data, although not entirely consistent, are just the
opposite; lower values are observed in hypertensives than in
normal individuals. You are correct that this constellation of
findings implies an alteration in the extracellular binding of
calcium and suggests that there is a circulating calcium-binding
protein that is increased in some hypertensive patients.
DR. Bu5HIN5KY: Do you believe that alterations in calcium
metabolism are a final common pathway or simply one compo-
nent, perhaps a small one, in the control of systemic blood
pressure?
DR. MCCARRON: I subscribe to the view that hypertension is
a heterogeneous disorder. We are never going to identify a
single explanation that accounts for a disorder like high blood
pressure that afflicts 40 million people in the United States. On
the other hand, altered calcium metabolism may be a factor for
15% to 30% of the population, as Witteman's recent report
suggests [49]. These prospectively gathered epidemiologic data
are consistent with the experience in the intervention trials. As
I tried to point out, somewhere between 30% and 45% of an
unselected population of hypertensives will respond favorably
to added dietary calcium in their daily regimen.
DR. KAI LAU (Director, Division of Nephrology, Michael
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Reese Hospital, Chicago): I have a very basic question. You
pointed out that vascular smooth muscle cells derived from
hypertensive animals have an attenuated transiency in response
to agonists. Also, you referred to data, perhaps unpublished,
showing that vascular smooth muscle cells pretreated with
parathyroid hormone or 1,25 dihydroxyvitamin D3 have an
attenuated response. Several laboratories, including our own,
have shown that cytosolic free-calcium concentrations almost
invariably reflect the metabolic and calcium balance status.
Data from Japan, the U.S., and Europe indicate that acute
changes in buffer calcium concentration elicit directional
changes in cytosolic free-calcium concentrations. Chronically,
dietary calcium manipulations also alter intracellular ionic
calcium levels in a directional fashion. Stated simply, cytosolic
free-calcium concentration is a very good indicator of the status
of calcium balance; it is high when an animal is fed a high-
calcium diet, and low when the animal is given a low-calcium
diet. The current accepted model of vascular smooth muscle
contraction indicates that an increase in the cytosolic free-
calcium level initiates and signals contraction. How do you
reconcile your data with these considerations, especially given
the observations that PTH and 1 ,25(OH)2D3 acutely raise
cytosolic free-calcium concentrations of virtually all cell sys-
tems examined?
DR. MCCARRON: It may be relatively easy to reconcile these
seemingly divergent observations. Observations by Dr. Bu-
koski at Oregon represent the first measurements of the calcium
transient in an intact resistance vessel. Any comparison with
other findings must be made cautiously. The observations you
are referring to have been gathered in isolated cells, and in
many cases the measurement of intracellular calcium has been
carried out in suspended cells, which means you are dealing
with a manipulated system. In the case of our data, the
mesenteric vessel is freshly isolated, then exposed to the
agonist, in this case, norepinephrine. Under these more physi-
ologic conditions, which come closer to mimicking the condi-
tions the vessel experiences in vivo, we have observed pre-
cisely what you predicted if intracellular calcium stores reflect
dietary intake and metabolic status. As we have proposed, high
blood pressure, in selected circumstances, is associated with
the patient's failure to maintain adequate calcium balance.
Based on that premise and your own observations, an attenu-
ation of the calcium transient is exactly what you would predict
and indeed what we have observed.
DR. LAU: If the calcium transient is related to the contractile
event, I don't understand why the increased vasoconstrictive
tone, reactivity, and contractility that are characteristic of the
hypertensive animal should not be associated with, or perhaps
causally related to, a higher calcium transient. Yet you demon-
strate an attenuated calcium transient.
DR. MCCARRON: Again, this is reconcilable. What you are
not taking into account is the association of established high
blood pressure with vascular smooth-muscle-cell hypertrophy.
It would be consistent to record a lower transient but a greater
pressor response simply because of structural changes. Re-
member, we are not saying that a rise in the intracellular
calcium did not occur in the SHR; we agree that contraction is
associated with a rise in the concentration of intracellular free
calcium. The transient does not have to be greater, provided
there are more cells to contract.
DR. DANIEL BATLLE (Associate Professor of Medicine,
Northwestern University Medical School, Chicago, Illinois): I
have a similar conceptual problem with your findings in vascu-
lar smooth muscle tissue where the agonist-induced calcium
transient was reduced in cells from the SHR as compared with
those from WKY rats. Studies in platelets and lymphocytes
have revealed not only a difference in cytosolic calcium under
resting conditions, that is, it is higher in cells from the SHR than
in those from WKY rats [181, 182], but also that the calcium
transient produced by thrombin was greater in platelets from
hypertensive than normotensive individuals [181]. 1 don't have
much problem in conceptualizing that, under steady-state con-
ditions, there may be no differences in cytosolic free calcium
between SHR and WKY cells. In fact, we have shown that this
is the case in suspensions of vascular smooth muscle cells
grown in culture [183] and in freshly dissociated renal tubular
cells [184]. I have a great deal of difficulty, however, accepting
the idea that agonist-induced calcium transient may be reduced
in cells from the SHR as compared with WKY cells.
DR. MCCARRON: The higher cytosolic free calcium values
noted in some cell lines derived from hypertensive animals or
humans is in no way inconsistent with what we have observed
in intact mesenteric arterioles [94] or with the hypothesis I have
advanced in this presentation. Remember, the calcium transient
we are measuring is precisely that: a transient, lasting a fraction
of a second. Then a cell must clear the free Ca2 released. This
latter step is highly dependent on the sarcolemmal and sarco-
plasmic membrane-imbedded Mg2-Ca2-ATPase pump. If, as
we have interpreted the data, there is an inherent defect in the
Mg2-Ca2-ATPase pump of the SHR and other hypertensive
species, one would expect to see higher intracellular free Ca2
values in chronically activated or stimulated cells, much as you
describe. The increased intracellular free calcium values would
reflect a defect in the clearance mechanism, that is, the Mg2-
Ca2-ATPase pump. We have to remain patient and consider
the possibility that the different cell systems and the various
ways in which we prepare them account for the differences
observed. As I have said, the Mg2-Ca2-ATPase pump differ-
ence could account for the difference when you start activating
a cell and you have it in suspension.
DR. SATISH KUMAR (Renal Fellow, Joint Michael Reese!
University of Chicago Program in Nephroiogy): Have any
studies showed a positive correlation between hypertension and
increased calcium intake or increased calcium levels in plasma?
DR. MCCARRON: No epidemiologic reports have noted higher
dietary calcium intakes in hypertensives. In fact, few studies
have shown the absence of a negative relationship; more than
20 reports have detected lower calcium intakes in association
with higher arterial pressure. Sempos et al claimed that the
calcium intake was similar for hypertensive and normotensive
subjects in their analysis of HANES land HANES II data [47].
Subsequently, they ackowledged that in HANES I there was an
inverse relationship based on an alternative statistical approach
[185]. So the dietary data base in the epidemiologic literature is
consistent. As for plasma calcium levels, the data are less
consistent. Several studies have indicated that serum total
calcium values are higher in hypertensive patients. In our own
experience, this finding appears to be most evident in females.
Other reports have suggested that serum total calcium values
are lower in the hypertensive individual [117], a finding similar
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to what has been observed for serum ionized levels, as I
mentioned.
DR. JORDAN J. COHEN (Dean of Medicine, State University
of New York at Stony Brook, Stony Brook, New York): In
considering nutritional factors in the pathogenesis of hyperten-
sion, one must acknowledge the overriding importance of
obesity. One of the most predictable ways to lower blood
pressure is through weight loss. Do you have a hypothesis that
would link calcium metabolism with this striking antihyperten-
sive effect of weight loss?
DR. MCCARRON: You are correct. If there is one demo-
graphic or physiologic variable that matches up with blood
pressure in virtually all societies, it is weight or body mass
index. Weight might account for as much as 70% of variation in
blood pressure in a given population. In our report on the
HANES I data, we noted an inverse relationship between
dietary calcium intake and body mass index within the United
States [29]. By that, I mean that greater consumption of dietary
calcium was associated with a lesser body mass index. Such an
association also has been noted by other investigators. These
are simply correlations and should not be used to argue for a
causal relationship. Recently Metz et al from our group re-
ported that in normal and hypertensive animals, body fat
content is reduced and lean body mass increased as dietary
calcium intake is increased [186]. The pathophysiologic mech-
anisms that would account for this association among dietary
calcium, blood pressure, and obesity are unknown but certainty
worth exploring. This relationship might represent a central-
nervous-system effect mediated through a change in thermo-
genesis [1871.
DR. BusI-IINsKY: Much of the data that you presented on the
hypertensive rat indicate an inherent abnormality in calcium
homeostasis. Yet you say that ingestion of more calcium will
lower blood pressure. These observations seem paradoxical
unless one argues that eating more dietary calcium overcomes
the disorder of calcium homeostasis. Can you link any homeo-
static abnormality with the results of dietary studies?
DR. MCCARRON: Increasing dietary calcium has lowered
blood pressure in at least three normotensive strains: the
Wistar, the Wistar-Kyoto, and the Fischer 344 rat [106—108]. An
experimental animal does not have to have an elevated blood
pressure to exhibit a reduction in blood pressure when addi-
tional calcium is consumed. That has also been the experience
in the human trials [121]. Furthermore, the influence of dietary
calcium intake on blood pressure has been noted in non-genetic
models of hypertension [105]. We need not speculate that
feeding supplemental calcium to selected individuals or labora-
tory models actually influences a genetic defect. But such an
intervention might modify systemic factors such as the calcium-
regulating hormones which, in turn, modify the expression of a
genetic defect. Based on our experience utilizing isolated ente-
rocytes derived from the SHR and WKY, we have been able to
demonstrate that a presumably genetically linked defect in
cytosolic flux of calcium is reversed by the ingestion of addi-
tional dietary calcium [76]. We have speculated that reversion
of this defect might reflect a change in the regulation of the
Mg2-Ca2-ATPase that results from the increased exposure of
the cell to calcium because that pump is regulated by both Ca24
and calmodulin.
In a separate system, the cultured myocyte, Bukoski and
coworkers demonstrated that changes in extracellular Ca2
within the physiologic range stimulate 45Ca uptake by the aortic
myocyte [139]. Independent of circulating factors, therefore,
changes in extracellular Ca2 appear to influence Ca2 trans-
port by the myocyte.
DR. LAu: I have some difficulty with the notion that there is
a renal calcium leak in genetic hypertension. The Ackerman
study showed a lower baseline calcium excretion rate in human
hypertensives and noted a higher calcium clearance only with
increased natriuresis during saline loading [188]. The same is
true of the study published several years ago in ClinicalScience
[141. Your own data could be criticized for comparing 2-hour
urine chemistries in fasting normals with 24-hour urine chem-
istries in hypertensives allowed ad-libitum food intake. Our
animal work is the only study using classic clearance techniques
and shows a reduction in calcium clearance in fasted hyperten-
sive rats compared with age-, gender- and diet-matched fasted
normotensive controls [189]. More fundamentally, your labora-
tory [781 and that of Chen Hsu at Ann Arbor (personal commu-
nication) reproduced our findings that there is an age depen-
dency in the changes in urinary calcium excretion rate [189].
Early on, these animals are actually hypocalciuric, not hyper-
calciuric. I have difficulty understanding why, in a genetically
transmitted disorder, the renal calcium leak postulated to
contribute to hypertension does not appear in the first 15 to 18
weeks of life, by which time hypertension is almost maximally
established. In fact, hypocalciuria is invariably present in the
younger animals. You and your coworkers recently published
an abstract showing that external calcium balance is also
increased at an early age in the spontaneously hypertensive rat.
In view of these findings, how can we conclude that calcium
deficiency is causally related to the genesis or maintenance of
hypertension?
DR. MCCARRON: These seemingly disparate findings may all
be very consistent. We agree that the very young SHR may be
in slightly greater net positive Ca2 balance than the WKY.
However, as DrUeke and coworkers have demonstrated, the
very same animals studied at 12 to 14 weeks of age show just the
reverse; that is, the SHR is no longer retaining an equivalent
amount of Ca2 compared with the WKY [78]. I should add that
this latter finding is consistent with your own report of Ca2
balance in the 10-week-old male SHR [112]. The question is
why are there these age-related transitions in the SHR's meta-
bolic systems that are responsible for maintaining calcium
balance? Currently we are pursuing the theoretical possibility
that the SHR at 4 weeks of age is able to maintain equal or
greater Ca2 retention than the WKY, but this comes at the
price of increased circulating levels of the Ca2-regulating
hormones (PTH and calcitonin) that have been demonstrated
during adolescence and the rapid growth that occurs at that
time. Even with the increased levels of the Ca2-regulating
hormones, the SHR's intestine and kidney are no longer able to
respond adequately, and negative Ca2 balance ensues. The
important unknown here is what is the cellular defect that
underlies the inability of the organs to respond appropriately?
Of equal importance is to understand how this defect relates to
the rapid rise in arterial pressure that also occurs during this
period. Most of the disturbances of calcium metabolism emerge
during the period when blood pressure is climbing most rapidly,
between about 8 and 20 weeks. Blood pressure plateaus after 25
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to 28 weeks, however, which is also when the animal stops
growing. The urinary calcium leak persists though [62].
DR. LAU: If there were a defect in calcium homeostasis, I
don't see why we would expect to find an increase in net
external calcium balance, even early on. That would imply, at
best, that we should expect near-normal or slightly reduced
calcium balance compared with the normotensive strain. In
published work, we have done experiments in both the female
and male and documented the higher blood pressure in female
SHR than in female WKY rats [151]. Van Os' group has
obtained the same results in the male. You have done it in the
male. So I think gender is not an issue here, as long as we
compare SHR with WKY rats of the same sex in a given study.
In my view, any definitive, global interpretation of the cumu-
lative data is somewhat premature.
Would you comment on the age-related changes in serum
concentration and in the synthesis of I ,25(OH)2D3? What if we
were to postulate that the apparent defect is actually a compen-
satory reduction in 1,25 dihydroxyvitamin D3 synthesis in
response to increased cumulative external calcium balance
and/or higher cumulative phosphorus balance? What if the
intracellular cytosolic free calcium levels in renal tubules in
SHR at 12 weeks of age were found to be increased, at an age
when I ,25(OH)2D3 production is down, serum levels of
l,25(OH)2D3 are reduced, and the corresponding duodenal
calcium transport is depressed? Couldn't the last three meta-
bolic changes merely reflect physiologic down-regulation? Why
couldn't we reconcile all these data, at least tentatively, by that
kind of interpretation?
DR. MCCARRON: I do not believe it is rational to treat male
and female SHR as equivalent models of hypertension. They
are not. Their blood pressure pattern is strikingly different, as is
their calcium metabolism. I should add that the situation is the
same in human hypertension. I would agree that one reasonable
interpretation of the intestinal Ca2 transport data and
1,25(OH)2 vitamin D3 data is that the reduction in the former
reflects a physiologic down-regulating response to the latter.
However, that interpretation ignores several important addi-
tional observations. If the reduced 1 ,25(OH)2 vitamin D3 levels
were simply the result of the SHR being in net positive Ca2
balance, then why would PTH and calcitonin concentrations be
increased and serum ionized Ca2 and phosphorus concentra-
tions be decreased? Furthermore, both Kawashima et al [66]
and Patel and Hsu [68] have documented that vitamin D1
production rates are reduced in the SHR's kidney. Finally,
whatever the state of Ca2 balance during any given phase, the
overall or lifetime effect appears to be abnormal; reasonably
good data provide evidence for a lower bone mineral content in
the adult male SHR as compared with the WKY [81, 82]. As
discussed earlier, where intracellular free Ca2 levels fit into
this schema remains relatively poorly defined at this time.
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